Mucosal administration type vaccine

Respiratory infections like COVID-19 and influenza are caused when pathogens like SARS-CoV-2 and influenza virus enter the body through the mucous membranes in the nose and throat.
In preventing these respiratory infections, prevention of virus infection itself at the mucosal surface of the nose and throat consider to be very important. Intranasal vaccines, designed to induce effective immunity at these mucosal sites, are therefore gaining traction.

Nasal vaccines have the advantage of reducing anxiety about injections and reducing the burden on medical staff, but there are still many issues that need to be overcome, such as the method of spraying and adjusting the dose administered into the nasal cavity. In collaboration with Chiba University Hospital, SHIONOGI has founded the "Division for Human Mucosal Vaccine Research"* to address these issues and advance the development of effective intranasal vaccines from both clinical and non-clinical aspects. We're also exploring the development of oral vaccines for easier administration in the future.

This study is part of AMED's SCARDA project for vaccine development and production infrastructure, and is receiving funding from this initiative.

Notice Regarding the Inclusion of Nasal Vaccine Research and Development for Influenza Virus and SARS-COV2 / New Modality Research and Development Project by AMED｜

Schematic diagram of nasal vaccine

* Shionogi Announces the Conclusion of a Contract for the Establishment of a Research

Department for Mucosal Vaccines with Chiba University Hospital. (Press Release, February 10, 2022)

https://www.shionogi.com/global/en/news/2022/2/e20220210.html

 

AMED

AMED stands for the Japan Agency for Medical Research and Development. Established in 2015, it serves as the national hub for medical research and development in Japan.

SCARDA

SCARDA stands for the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response. The center is tasked with collecting and analyzing information related to vaccine development and providing the necessary funding to facilitate research and development initiatives.